Join us:
January 10–12, 2022 in-person in San FranciscoJanuary 17–19, 2022 virtually

Nick Leschly
Chief Bluebird at bluebird bio

Profile

Nick Leschly has served as chief bluebird since September 2010. bluebird bio (BLUE) is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer. The driving vision is to Make Hope A Reality for many patients and their families by bringing True Blue (ideal state for patients) to life through Blue Mojo (innovative, resilient and purpose driven culture). Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE (multiple myeloma treatment). He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He serves on the board of Biotechnology Innovation Organization (BIO) and Synlogic (SYBX). He also serves on the advisory boards for Princeton University Molecular Biology Department and the Special Olympics of Massachusetts. Nick is extremely happily married to his high school sweetheart and has five teenage daughters.

Agenda Sessions

  • Leveraging platform approaches to gene therapies to accelerate therapeutic development for monogenic diseases

    On Demand